Pfizer-Olema Collaboration Targets Metastatic Breast Cancer

Pfizer Inc. (NYSE:PFE) is among the undervalued wide moat stocks to buy now. Olema Pharmaceuticals has announced its collaboration and supply agreement with Pfizer Inc. (NYSE:PFE) in the treatment of metastatic breast cancer. Under the clinical trial partnership, both companies will examine the palazestrant-atirmociclib combination in approximately 35 patients, anticipated to begin in H2 2025.

With Olema leading the study, Pfizer Inc. (NYSE:PFE) will serve as the supplier of atirmociclib for use in the Phase 1b/2. As stated by Sean P. Bohen, the President and Chief Executive Officer of Olema Oncology,

“We are excited to assess this combination in the clinic as we seek to establish palazestrant as a potential backbone endocrine therapy for metastatic breast cancer.”

Known to everyone since the COVID days, Pfizer Inc. (NYSE:PFE) has demonstrated a performance that is nothing short of excellence. From richer profit margins and expanding cash flows to an overall improved balance sheet, the company has showcased financial resilience. With that being said, new acquisitions and partnerships are just the cherry on top, supporting the giant’s 2030 growth outlook.

Pfizer Inc. (NYSE:PFE) is a New York-based biopharmaceutical company that develops and sells medicines and vaccines in several therapeutic areas. Founded in 1849, the company is committed to breakthroughs that transform people’s lives.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.